Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacia and Upjohn Expands Deal with Incyte

Premium

PALO ALTO, Calif.-- Incyte Pharmaceuticals expanded its genomic database deal with Pharmacia and Upjohn this month, giving Pharmacia license to use Incyte's PathoSeq database of microbial genomic information. Since its relationship with Incyte was formed in 1994, Pharmacia has obtained access to a series of Incyte LifeSeq databases containing human gene sequence and expression data, full-length genes, and gene mapping information, as well as Incyte's ZooSeq animal database. The companies said Pharmacia would use the PathoSeq data in its infectious disease programs. Roy Whitfield, Incyte's CEO, said the addition of PathoSeq to Pharmacia's research and development process will allow drug developers to cross-reference human, animal, and microbial data "to uncover relationships between species and develop better-targeted therapies."

PathoSeq contains genomic data for more than 40 bacterial and fungal microorganisms. Incyte will receive annual access fees and could receive royalties on sales of products developed by Pharmacia with Incyte technology and data.

Filed under

The Scan

Fertility Fraud Found

Consumer genetic testing has uncovered cases of fertility fraud that are leading to lawsuits, according to USA Today.

Ties Between Vigorous Exercise, ALS in Genetically At-Risk People

Regular strenuous exercise could contribute to motor neuron disease development among those already at genetic risk, Sky News reports.

Test Warning

The Guardian writes that the US regulators have warned against using a rapid COVID-19 test that is a key part of mass testing in the UK.

Science Papers Examine Feedback Mechanism Affecting Xist, Continuous Health Monitoring for Precision Medicine

In Science this week: analysis of cis confinement of the X-inactive specific transcript, and more.